AKERO THERAPEUTICS INC (AKRO) Stock Price, Forecast & Analysis
USA - NASDAQ:AKRO - US00973Y1082 - Common Stock
AKRO Key Statistics, Chart & Performance
The current stock price of AKRO is 54.25 USD. In the past month the price increased by 0.76%. In the past year, price increased by 93.13%.
AKRO Latest News, Press Relases and Analysis
AKRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About AKRO
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Company Info
AKERO THERAPEUTICS INC
601 Gateway Boulevard, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Andrew Cheng
Employees: 67
Phone: 16504876488
AKERO THERAPEUTICS INC / AKRO FAQ
Can you describe the business of AKERO THERAPEUTICS INC?
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
What is the current price of AKRO stock?
The current stock price of AKRO is 54.25 USD. The price increased by 0.09% in the last trading session.
Does AKERO THERAPEUTICS INC pay dividends?
AKRO does not pay a dividend.
What is the ChartMill rating of AKERO THERAPEUTICS INC stock?
AKRO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of AKERO THERAPEUTICS INC (AKRO)?
AKERO THERAPEUTICS INC (AKRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
Would investing in AKERO THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AKRO.
What is the employee count for AKRO stock?
AKERO THERAPEUTICS INC (AKRO) currently has 67 employees.
AKRO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AKRO. When comparing the yearly performance of all stocks, AKRO is one of the better performing stocks in the market, outperforming 93.12% of all stocks.
AKRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AKRO. No worries on liquidiy or solvency for AKRO as it has an excellent financial health rating, but there are worries on the profitability.
AKRO Financial Highlights
Over the last trailing twelve months AKRO reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -31.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.12% | ||
| ROE | -30.58% | ||
| Debt/Equity | 0 |
AKRO Forecast & Estimates
16 analysts have analysed AKRO and the average price target is 64.26 USD. This implies a price increase of 18.45% is expected in the next year compared to the current price of 54.25.